The effect of exposure to pulsing electromagnetic fields on migraine activity was evaluated by having 42 subjects (34 women and 8 men), who met the International Headache Society's criteria for migraine, participate in a double-blind, placebo-controlled study. Each subject kept a l-month, pretreatment, baseline log of headache activity prior to being randomized to having either actual or placebo pulsing electromagnetic fields applied to their inner thighs for 1 hour per day, 5 days per week, for 2 weeks.
Two pilot studies' have been conducted in which 23 chronic migraineurs were exposed to pulsing electromagnetic fields (PEMFs) over their inner thighs. In the open pilot study, 1 I subjects kept a 2-week, pretreatment, baseline headache log before and after 2 to 3 weeks of exposure to PEMFs for 1 hour per day, 5 days per week.
The number of headaches per week decreased from 4.03 during the baseline period to 0.43 during the initial 2-week follow-up and to 0.14 during the extended followup which averaged 8.1 months. In the double-blind pilot study, 9 subjects kept a 3-week log of headache activity and were then randomly assigned to receive 2 weeks of real or placebo PEMF exposures as described above. The 6 subjects exposed to the actual device first showed a change in headache activity from 3.32 per week to 0.58 per week. Three additional subjects in the blind study inadvertently received only half power and showed no change in headache activity. These results were sufficiently encouraging that undertaking a placebo-controlled study of the technique appeared to be worthwhile.
Pulsing electromagnetic fields have been in use as
therapeutic modalities for at least 40 years. The PEMF units used in our studies (Diapulse, model D 103,  Diapulse, Inc of New York) are set to produce pulsed, high-frequency, high-peak power, electromagnetic energy at a frequency of 27.12 mHz in 65 microsecond bursts occurring in 600 pulse per second sequences at 975 peak watts. This is sufficient power to light a 60-watt bulb placed into the field. The field extends about 12 cm from the unit's head in a conical pattern. The unit's head is placed just above the area to be exposed and turned on for a set amount of time. The Diapulse device looks like a floor-mounted hair dryer from the 195Os, has a relatively loud fan, a ticking timer, and sufficient knobs, lights, meter, etc to be quite impressive. 1
Exposure to PEMFs of the type described above appears to result in at least a temporary increase in peripheral blood flow. For example, Erdman2 recorded peripheral blood flow from 20 normal subjects using both a temperature probe and volumetric measurements while they were being exposed to PEM-generated fields. He found a high correlation between the amount of energy produced by the The type of log used in this study required the minimum possible subject compliance while gathering the most crucial data. It only required subjects to make one entry after each headache. The initial version required subjects to enter the date of occurrence, duration, worst and average intensity of the headache, and medications or other interventions utilized. The final version (used with most of the subjects) also required information about vomiting, description of the pain, and presence or absence of an aura. AndrasikQ has recently endorsed this approach for the type of discontinuous headaches we evaluated and used it successfully in at least one study.5 The minimum duration for an adequate evaluation of migraine activity has been establishedto and was exceeded by the monthlong log utilized in this study.
METHODS
Design.-Subjects were diagnosed as having either migraine with aura or migraine without aura. All partici-pants kept a l-month, preexposure, baseline log. They were then randomized into real or placebo exposure groups with half the subjects receiving actual exposure to PEMFs and half receiving placebo exposure for 2 weeks.
This was followed by a minimum of a l-month follow-up during which subjects continued to keep the log every time they had a headache.
After the first month following exposure, patients were offered use of a working generator with the same exposure parameters as during the initial exposure period.
Thus, patients failing to benefit from the initial exposure Three of the subjects who had migraine by history did not have any headaches which met the criteria for migraine during participation. Their headaches did meet the criteria for tension-type headaches, therefore, they were removed from the study and their data are reported separately.
Procedure.-Once subjects met the entrance criteria and consented to participate in the study, they were told to continue their current medications without significant change and were given a headache activity log (described in the introduction) to keep for 1 month. At the end of the month, they were randomized to be exposed to either actual or placebo PEMFs by a computer-generated algorithm which insured that the subjects would be evenly distributed after each 20 randomizations. Evaluation of Headache Activity.-Subjects kept the log which listed headache frequency, duration, and intensity as well as use of headache-related medications throughout the entire period of participation. Pain intensity was rated on a visual analog scale, which has been shown to be highly reliable and effective.'2 Pain was rated on a scale of 0 (no pain) to 10 (so much pain that they would faint if they had to sustain it for 1 more second). The log we used is typical of those shown to be highly efficacious and required only one entry per headache. Exposure to PEMFs or Placebo.-Afier keeping the initial baseline log for 1 month, subjects were exposed to PEMFs (real or placebo) on the thigh at a power/frequency setting of 61600 for 1 hour per day, 5 days per week, for 2 weeks. The pilot results indicated that 2 weeks should have been sufficient for any effect likely to occur. The fields were directed to the thigh because it worked during the pilot study and the major blood vessels for the leg pass under that position. Neither the therapist exposing the subject nor the subject knew which group they were in. Only the therapist assigned to calibrate the devices knew which was which. The machines required calibration at least twice a week due to random loss of power every few weeks. Participants could not feel the machine working, so they could not tell which group they were in. However, each was asked whether they thought they were in the real or placebo group by having each rate how certain they were they had received the real treatment on a scale of 0 to 10, where 0 is not at all certain and 10 is sure they had received the real treatment.
The placebo machine was identical to the functioning machine both in looks (lights, dials, etc) and sounds (fan, timer noise, etc). The only difference was that several crucial tubes had been removed so it produced no field. As subjects could not sense the field, there was no way for them to know which machine was actually functioning.
Data Analysis and Presentation.-Changes in
headache activity were determined solely from the log kept for a month before and after each intervention. Differences in proportion of subjects having headaches were analyzed using the z test for differences in proportions.
Changes in each subject's headache activity are pre- Subjects were exposed to the actual device after the initial l-month follow-up Each exposure period consisted of daily, l-hour exposures, five times per week, for 2 weeks.
Frequency indicates number of headaches per week, intensity of headache (on a scale of 0 to lo), duration of headache in hours. * Overall outcome is the composite result of changes in frequency, duration, and intensity of headaches as well as amount of associated discomfort (eg, vomiting) and medication use over the course of participation: W indicates worse, more than a 10% increase in at least two variables with no decrease in others; NC no change, differences less than 10% of baseline activity on all variables; M minor decrease, decrease in headache activity of 10% to 19% on at least two variables; G good decrease, decrease of over 20% on at least two variables; E excellent decrease, headaches gone or nearly gone (less than one half hour in duration, pain intensity less than 2 on a 0 to IO scale, frequency less than twice a month).
t Subject's rating of how certain they were they received actual exposure, on a scale of 0 to IO with 10 being certain. $ Log was lost in transit. subject reported no change in headaches.
sented as a composite score derived from changes in freactivity (38% good, 38% excellent). A z test for difference quency, duration, intensity, medication use, and ratings of in proportions indicates that the actual exposure and placeassociated discomfort (eg, vomiting). This method was bo groups did not differ significantly after 2 weeks of chosen over presenting the individual measures in order to exposure (z 1.53, P=. 13) but did after 4 weeks of exposure make the overall results easier to follow. The individual (z 2.41, P=.O16). As the group who received actual expomeasures for each subject are reported in Tables appearing sure for 2 weeks continued to improve after their first in the "Results" section. As can be seen from these tables, follow-up month, the overall rate of response to actual the overall change in group headache is obscured by the exposure at 2 months follow-up was 95% which is also variety of idiosyncratic changes shown by the subjects significantly different from the placebo response (z 2.75, comprising each group. F=.OO6).
The composite scores were derived as follows:
"worse" was defined as more than a 10% increase in at least two variables with no decrease in others; "no change"
was defined as differences less than 10% of baseline activity on all variables; "minor decrease" was defined as a decrease in headache activity of 10% to 19% on at least two variables; a "good decrease" was defined as a decrease of over 20% on at least two variables; and an "excellent decrease" was when headaches were gone or nearly gone (less than l/2 hour in duration, pain intensity less than 2 on 0 to 10 scale, frequency less than two per month).
When only significant improvement (good and excellent responses) is considered, 4 of the 20 subjects receiving placebo showed good improvement and none showed excellent improvement (a 20% placebo response). Twenty of the 30 subjects given inadequate (2-week) actual exposure showed good to excellent improvement (a 67% response rate). These response rates are statistically different (z 2.7, P=.OO7).
Individual responses are detailed in Tables 2 and 3 and the results are summarized in Table 4 .
The three subjects who only had tension-type headaches during the study period were not included in the overall analysis. All happened to be in the actual exposure group and none responded to exposure. One had chronic daily headaches at an average intensity of about 3 which did not respond to 2 weeks of actual exposure. The second subject had an average of one headache per week at an average intensity of 5, both before and after exposure to the actual device for 2 weeks during the blinded stage and to the active device for an additional 2 weeks. The third subject had headaches about 2 out of every 3 days at an average intensity of about 2, which did not respond to 2 weeks of actual exposure.
RESULTS
Only one subject dropped out before completing the initial 2 weeks of exposure. However, three subjects dropped out of the study before sending in their l-month follow-up logs. One of the dropouts received the placebo and two received actual exposure. No data were gathered for these subjects as they did not return their logs.
Dropouts were replaced by the next subject joining the study.
Seventy-three percent of those receiving actual exposure initially showed decreased headaches (45% good, 14% excellent). Eight of these subjects received an addi- Each exposure period consisted of daily, l-hour exposures, five times per week, for 2 weeks. Frequency indicates number of headaches per week, intensity of headache (on a scale of 0 to lo), duration of headache in hours. * Overall outcome is the composite result of changes in frequency, duration, and intensity of headaches as well as amount of associated discomfort (eg, vomiting) and medication use over the course of participation: W indicates worse, more than a 10% increase in at least two variables with no decrease in others; NC no change, differences less than 10% of baseline activity on all variables; M minor decrease, decrease in headache activity of 10% to 19% on at least two variables; G good decrease, decrease of over 20% on at least two variables; E excellent decrease, headaches gone or nearly gone (less than one half hour in duration, pain intensity less than 2 on a 0 to 10 scale, frequency less than twice a month). p Subject's rating of how certain they were they received actual exposure, on a scale of 0 to 10 with 10 being certain. (38) 318 (38) 618 (75) 1 from no change 2 from no change * Composite result of changes in frequency, duration, and intensity of headaches as well as amount of associated discomfort (eg, vomiting) and medication use over the course of participation: worse indicates more than a 10% increase in at least two variables with no decrease in others; no change, differences less than 10% of baseline activity on all variables; minor decrease, decrease in headache activity of 10% to 19% on at least two variables; good decrease, decrease of over 20% on at least two variables; excellent decrease, headaches gone or nearly gone (less than one half hour in duration, pain intensity less than 2 on a 0 to 10 scale, frequency less than twice a month). t Nonresponse rate would have been 7/22 (32%) if reported tension headaches were included in the analysis.
to the placebo effect did not participate in this part. This enhanced our ability to differentiate placebo from actual effects. Subjects from both groups who did not show improvement were permitted to volunteer because the therapists did not know which was the actual exposure group. This complex process was required because our initial attempt at performing a standard crossover study* failed when subjects receiving actual exposure initially would not cross over to a placebo arm because their headaches had decreased significantly. A washout period was impractical because their headaches did not return for the entire follow-up period which averaged 8.1 months.
The decrements in headache activity during the open pilot study using this device' were far superior to those of the initial 2-week exposure to the actual device in this study. It is very likely that the difference is at least partially due to the exposure period of the open pilot being one third longer than provided by this study's initial exposure period. This possibility is validated by the increase in effectiveness from 73% to 100% upon an additional 2 574 weeks of exposure following the l-month follow-up for those subjects requesting the second exposure. A second reason this study may have produced lower improvement rates may be that the subjects were more typical of average patients with migraine as they had headaches an average of 2.3 times per week which fits the accepted standards for migraine," while the subjects in the open pilot were specifically selected as being "worst case" patients who had failed everything and had headaches an average of 4.3 times per week. A third possible reason for the difference was that subjects in the pilot study all ceased using preventive medications prior to initiation of exposure, while those in this study were not required to do so. During the double-blind portion of the study, the participants' rating of their belief that they received actual exposure was random with respect to whether they really received actual exposure. Thus, knowledge of which group the subject was in did not affect the results.
Neither migraine of traumatic origin nor tension headaches appear to respond to PEMFs. For four partici-
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pants who had mixed headaches, it was possible to identify tension headaches in every log with a high degree of probability as they met all the criteria for tension-type headache and none for migraine. The rate of occurrence of these headaches remained approximately constant throughout participation while the rate of migraine dropped. When the data from these subjects were reevaluated eliminating the tension headaches, the subjects appeared to do much better than they did when the tension headaches were included. Thus, it is very likely that their migraines were decreasing while their tension headaches were holding steady.
Several of the subjects with mixed headaches reported that as the number of migraines decreased, they seemed to be getting more tension headaches. These "new" tension headaches occurred about as frequently as the migraines had been occurring. These individuals had usually indicated pain in the neck and shoulders along with symptoms of migraine during a "migraine." Thus, it is possible that concurrent tension headaches of which the subjects had not been previously aware were still occurring but were now noticed because the more intense migraines were no longer masking them.
The literature reviewed in the introduction indicates that the particular PEMF generator used in this study probably has some ability to increase peripheral blood flow.
The same body of evidence does not seem to exist for the weaker battery-powered units, magnetic field generators which do not pulse, or permanent magnets. If the working hypothesis (that increased peripheral blood flow has resulted in decreased headache activity) is correct, then devices not capable of increasing peripheral blood flow to a similar extent may not be effective. This is supported by the three patients in the pilot study who received half the normal exposure, failing to show any change in headache activity.
